Clinical trials: bipolar
Bipolar Disorder, Schizophrenia
Treatment of Mania Symptoms With Drug Therapy
This study will determine the effectiveness of three different drug therapies in treating the symptoms of mania.
- Trial name
- NCT00183443
- Testing
- Divalproex-extended release (DVP-ER), Lithium, Quetiapine
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Palo Alto Veterans Institute for Research
Bipolar Disorder I, Bipolar Disorder II
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
This is an open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in the treatment of participants with bipolar I/II disorder with a current major depressive episode.
- Conditions
- Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
- Trial name
- NCT03692910
- Testing
- SAGE-217
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Biogen
Schizophrenia, Bipolar Disorder
Skills Training to Enhance Vocational Outcomes in Veterans With Serious Mental Illness
Maintenance of employment is dependent upon being able to successfully integrate into one's work setting. This can present a significant challenge to individuals with serious mental illness, as they typically exhibit impairment…
- Conditions
- Schizophrenia, Bipolar Disorder, Psychotic Disorders
- Trial name
- NCT02663349
- Testing
- Social Cognition and Intervention Training
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Bipolar Depression
Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression
The purpose of the study is to compare the sedation profile one hour after dose administration between Seroquel IR and Seroquel XR.
- Trial name
- NCT00926393
- Testing
- Quetiapine Immediate Release, Quetiapine Extended Release
- Volunteers
- 139 people
- Sponsor
- AstraZeneca
Schizophrenia, Bipolar Disorder
Mobile Self-Tracking of Mental Health
Serious mental illnesses require years of monitoring and adjustments in treatment. Stress, substance abuse or reduced medication adherence cause rapid worsening of symptoms, with consequences that include job loss, homelessness…
- Conditions
- Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Post-traumatic Stress Disorder
- Trial name
- NCT05023252
- Testing
- mobile application
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- VA Office of Research and Development
Bipolar Disorder
Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder
This study will examine whether extended release galantamine, a drug approved by the Food and Drug Administration to reduce cognitive impairments in people with Alzheimer's disease, can perform the same function in stable people…
- Trial name
- NCT00741598
- Testing
- Galantamine-ER
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Bipolar I Disorder, Bipolar II Disorder
Gabapentin for Bipolar & Cannabis Use Disorders
The proposed 2-week, double-blind, crossover, proof of concept study aims to measure and manipulate core neurochemical (i.e., dysregulated brain GABA/glutamate homeostasis) and neurobehavioral (i.e., elevated impulsivity)…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Substance Use Disorders
- Trial name
- NCT03334721
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Medical University of South Carolina
Bipolar Depression
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
The primary objective of this study is to evaluate the superior efficacy of quetiapine extended release(XR) mono-therapy, administered once daily compared to placebo, in the treatment of depressive symptoms in patients with…
- Trial name
- NCT01256177
- Testing
- Quetiapine Fumarate (SEROQUEL) Extended Release
- Where
- 12 sites in China
- Volunteers
- 361 people
- Sponsor
- AstraZeneca
Bipolar Depression
A Phase III Study of SM-13496 in Patients With Bipolar I Depression.
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with Bipolar I Depression.
- Trial name
- NCT01986101
- Testing
- SM-13496
- Where
- 8 sites in Japan, Lithuania and 6 more
- Volunteers
- 525 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Bipolar Disorder
High Deductible Health Plans and Bipolar Disorder
Using eleven years (2004-2014) of claims data from the largest US commercial health insurer, the investigators will assess the impact of switching into high-deductible health plans (HDHPs) on outcomes for patients with bipolar…
- Trial name
- NCT02560701
- Testing
- Patient Interview
- Volunteers
- 350,823 people, healthy volunteers welcome
- Sponsor
- Harvard Pilgrim Health Care
Bipolar Disorder
A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar Disorder
Individuals with bipolar suffer from problems in basic cognitive skills such as memory and concentration. Unfortunately, there are no current treatments that have been shown to improve cognitive skills among individuals with…
- Trial name
- DCS (NCT01934972)
- Testing
- CR + DCS (D-cycloserine)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Arizona
Bipolar Disorder, Elderly
Long-term Study of FK949E in Elderly Bipolar Disorder Patients
FK949E was administered to elderly bipolar disorder patients with major depressive episode for 52 weeks. Its safety, efficacy, and plasma concentration change were evaluated in an open-label manner.
- Trial name
- NCT01737268
- Testing
- FK949E
- Where
- 32 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Astellas Pharma Inc
Schizophrenia, Bipolar Disorder
Aripiprazole Open-Label, Safety and Tolerability Study
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
- Trial name
- APEX 241 (NCT00102518)
- Testing
- Aripiprazole
- Where
- 50 sites in United States
- Volunteers
- 325 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders
Children between the ages of 5-17 years old who have or display symptoms of emotional dysregulation (explosiveness, mood swings, irritability, and/or violent behavior) are invited to participate in a 12-week research study to…
- Trial name
- NCT02357290
- Testing
- Open-label Treatment with N-Acetylcysteine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Psychosis
Effectiveness of Cognitive Remediation in a Supported Education Setting
The purpose of this study is to determine whether cognitive remediation as an adjunct to supported education, will result in improved cognitive functioning, symptoms, and performance in academic domains for persons with psychosis…
- Trial name
- NCT01492439
- Testing
- Cognitive Remediation, Supported Education
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar I Disorder
This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296
This is an open-label, multi-center,12 week extension study designed to evaluate the longer term safety, tolerability and effectiveness of lurasidone, flexibly dosed, adjunctive to lithium or divalproex for the treatment of…
- Trial name
- PERSISTExt (NCT01575561)
- Testing
- Lurasidone
- Where
- 71 sites in United States, Argentina and 10 more
- Volunteers
- 377 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depression, Bipolar
Depakote ER in Bipolar Depression
The purpose of this study is to examine the safety and efficacy of Depakote ER in bipolar depression and to evaluate metabolic and GABA changes with Depakote ER administration using PET and MRI/MRS brain imaging techniques.
- Trial name
- NCT00186186
- Testing
- Depakote ER
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Stanford University
Bipolar Disorder
Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs
A prospective, large, pragmatic, randomized trial to study the impact of METFORMIN and healthy lifestyle intervention (LIFE) vs.
- Trial name
- MOBILITY (NCT02515773)
- Testing
- Metformin, healthy lifestyle intervention (LIFE)
- Where
- 29 sites in United States
- Volunteers
- 1,565 people
- Sponsor
- Melissa Delbello
Bipolar Disorder
Prevention of Relapse & Recurrence of Bipolar Depression
The purpose of this study is to determine whether the long-term use of combined antidepressant plus mood stabilizer therapy is superior to mood stabilizer therapy alone in preventing the relapse and recurrence of bipolar…
- Trial name
- NCT00961961
- Testing
- Lithium / Fluoxetine
- Where
- 2 sites in United States
- Volunteers
- 177 people
- Sponsor
- University of Pennsylvania
Bipolar Disorder
Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode
To evaluate the effectiveness of an algorithm for Bipolar Disorder depressive episodes (BDD) using medications available in the Brazilian Public Healthcare System (SUS).
- Trial name
- NCT02918097
- Testing
- Lithium Carbonate, Sertraline, Nortriptyline
- Volunteers
- 78 people
- Sponsor
- Federal University of Rio Grande do Sul